Prostate cancer stands among the most common types of malignancy affecting males globally since early detection through accurate methods produces effective treatments and better survival statistics. Standard prostate cancer diagnostic procedures that begin with serum prostate-specific antigen (PSA) examinations combined with biopsies encounter various problems, which include misleading test results, combined with medical screening errors, and restricted healthcare accessibility within areas with scarce medical resources. The chapter investigates point-of-care (POC) biosensor technologies, which represent a revolutionary approach to provide decentralized early prostate cancer diagnostics of a personalized nature. The discussion focuses on the various biosensor techniques, which include electrochemical systems as well as optical devices and microfluidic and paper-based devices used for quick biomarker detection of prostate cancer markers such as PSA and prostate cancer antigen 3, TMPRSS2: ERG, and exosomal microRNAs. More emphasis is given to technological developments that allow real-time testing together with multiplexing functions and smartphone incorporation for enhancing diagnostic capability alongside patient adherence. The book critiques clinical biosensor applications using commercial products along with real-world case studies, yet it discusses analytical limitations, software validation requirements, and human-centered design challenges faced during development. The text defines upcoming directions, which show how biosensors merge with telemedicine platforms and artificial intelligence processors, as well as individualized medicine infrastructure. The chapter guides the strategic development and worldwide implementation of POC prostate cancer diagnostic methods through the end. The ongoing development of these technologies enables significant improvement of diagnostic delays and health equity in conjunction with new possibilities for prostate cancer management.